Skip to main content

Table 6 Indirect comparison results: duloxetine vs. gabapentin.

From: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Outcome Indirect treatment comparison (δ)
Mean (median)
95% CI for δ Between-study variance (τ 2)
Mean (median)
95% CI for τ 2
Efficacy     
Reduction in 24-hour pain intensity 0.270 (0.266) (-0.469; 1.022) 0.041 (0.013) (0.001; 0.247)
Tolerability     
Premature study discontinuation due to:     
- Lack of efficacy 0.067 (0.065) (-1.988; 2.116) 0.177 (0.028) (0.001; 1.281)
- Adverse events 0.841 (0.835) (-0.348; 2.065) 0.062 (0.015) (0.001; 0.406)
- Other -0.245 (-0.252) (-1.527; 1.075) 0.060 (0.015) (0.001; 0.386)
Diarrhoea -0.244 (-0.246) (-1.645; 1.164) 0.273 (0.051) (0.001; 1.825)
Dizziness -1.044 (-1.054) (-2.258; 0.183) 0.090 (0.021) (0.001; 0.590)
Headache -0.689 (-0.697) (-1.986; 0.638) 0.053 (0.013) (0.001; 0.348)
Nausea 0.704 (0.700) (-0.567; 2.021) 0.085 (0.022) (0.001; 0.529)
Somnolence -0.101 (-0.107) (-1.249; 1.078) 0.080 (0.016) (0.001; 0.545)
  1. Note:
  2. δ is the mean difference in treatment effect between DLX and each comparator.
  3. τ 2 is between-study heterogeneity.